Although most common loci of intracranial primary germinoma (IPG) are pineal and suprasellar regions, there are some reports of unusually located IPG which makes confusion of differential diagnosis of the tumor. Especially within posterior fossa area, IPG is hardly considered because of its extreme rareness and unmatched clinical characteristics comparing with supratentorial IPGs. Most usual areas within posterior fossa are known as fourth ventricle and medullar oblongata. With the best of our knowledge, there are only less than twenty reported cases of fourth ventricle IPG, yet. Herein, we presents a case of 24 years old female patient who had a large fourth ventricle tumor which turned out to be germinoma. The tumor had been suspected as an ependymoma with consideration of age of patient and features of imaging findings. But, intraoperative and pathologic findings were differ from ependymoma, and finally defined as a germinoma. After chemotherapy with consecutive radiation therapy, complete remission of the tumor without neurological complications was acquired.
NOW ENROLLING
Phase 2b study of IGV-001 in patients with newly diagnosed glioblastoma (NCT04485949)

OBJECTIVES

PRIMARY OBJECTIVE
Progression-free survival

SECONDARY OBJECTIVE
Overall survival

SAFETY OBJECTIVE
Safety and tolerability

CRITERIA

Key Inclusion Criteria
Patients who take part in the trial* must:
• Have newly diagnosed glioblastoma
• Be 18 to 70 years of age
• Have a KPS score ≥70 (unable to work but able to care for themselves overall)

Key Exclusion Criteria
Patients are not allowed to participate* in the trial if they have:
• A tumor that is on both sides of the brain
• Had previous surgery or anticancer treatment for glioblastoma
• Glioblastoma that came back
• Another cancer† while having glioblastoma or within the last 3 years that is not cured
• A weakened immune system (example: HIV, HBV, HCV) or an autoimmune disorder (example: Crohn's disease)
• Heart disease or history of heart issues

LEARN MORE
imvax.com/patients-families

LEARN MORE
clinicaltrials.gov/ct2/show/NCT04485949

*Additional criteria apply. Please refer to protocol 14379-201 for full inclusion and exclusion criteria. †Patients can participate if they had some skin cancers, superficial bladder cancer (cancer that was only on the surface of the lining of the bladder), or carcinoma in situ (cancer that had not spread) of the cervix or breast that had been cured.